Regulation of N6‐methyladenosine modification in erythropoiesis and thalassemia

Yanping Zheng,Siyang Lin,Meihuan Chen,Liangpu Xu,Hailong Huang

DOI: https://doi.org/10.1111/cge.14518

2024-03-16

Clinical Genetics

Abstract:N6‐methyladenosine modification (m6A) is the most abundant modification in mRNA and regulates RNA splicing, translation, stability, and so forth. m6A modification plays an essential role in erythropoiesis, ineffective erythropoiesis, and fetal hemoglobin expression. An in‐depth understanding of m6A modification provides a new treatment perspective of thalassemia. In eukaryotic RNA, N6‐methyladenosine (m6A) is a prevalent form of methylation modification. The m6A modification process is reversible and dynamic, written by m6A methyltransferase complex, erased by m6A demethylase, and recognized by m6A binding proteins. Through mediating RNA stability, decay, alternative splicing, and translation processes, m6A modification regulates gene expression at the post‐transcriptional level. Erythropoiesis is the process of hematopoietic stem cells undergoing proliferation, a series of differentiation and maturation to form red blood cells (RBCs). Thalassemia is a common monogenic disease characterized by excessive production of ineffective RBCs in the peripheral circulation, resulting in hemolytic anemia. Increasing evidence suggests that m6A modification plays a crucial role in erythropoiesis. In this review, we comprehensively summarize the function of m6A modification in erythropoiesis and further generalize the mechanism of m6A modification regulating ineffective erythropoiesis and fetal hemoglobin expression. The purpose is to improve the understanding of the pathogenesis of erythroid dysplasia and offer new perspectives for the diagnosis and treatment of thalassemia.

genetics & heredity